Drug Profile
JNJ 26489112
Alternative Names: 14C-JNJ-26489112; 26489112; JNJ-26489112Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Antidepressants; Antiepileptic drugs
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy; Major depressive disorder
Most Recent Events
- 01 Oct 2013 Discontinued - Phase-I for Epilepsy (in volunteers) in Belgium (PO)
- 01 Oct 2013 Discontinued - Phase-II for Epilepsy in USA (PO)
- 12 Mar 2012 Discontinued - Phase-II for Depressive disorders in USA (PO)